<SEC-DOCUMENT>0001213900-21-062812.txt : 20211201
<SEC-HEADER>0001213900-21-062812.hdr.sgml : 20211201
<ACCEPTANCE-DATETIME>20211201144546
ACCESSION NUMBER:		0001213900-21-062812
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20211201
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20211201
DATE AS OF CHANGE:		20211201

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			180 Life Sciences Corp.
		CENTRAL INDEX KEY:			0001690080
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				813832378
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38105
		FILM NUMBER:		211462588

	BUSINESS ADDRESS:	
		STREET 1:		830 MENLO AVENUE, SUITE 100
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025
		BUSINESS PHONE:		650-507-0669

	MAIL ADDRESS:	
		STREET 1:		830 MENLO AVENUE, SUITE 100
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	KBL MERGER CORP. IV
		DATE OF NAME CHANGE:	20161115
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea151570-8k_180lifesci.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:ATNF="http://180lifesciences.com/20211201">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_03E_ATNF_180lifesciences.com_20211201 -->
<!-- Field: Set; Name: xdx; ID: xdx_045_20211201_20211201 -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DEntityCentralIndexKey_0001690080 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2021-12-01to2021-12-01" name="dei:EntityCentralIndexKey">0001690080</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-12-01to2021-12-01" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="atnf-20211201.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2021-12-01to2021-12-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-12-01</xbrli:startDate>
        <xbrli:endDate>2021-12-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-12-012021-12-01_custom_CommonStockParValue0.0001PerShareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ATNF:CommonStockParValue0.0001PerShareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-12-01</xbrli:startDate>
        <xbrli:endDate>2021-12-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-12-012021-12-01_custom_WarrantsToPurchaseSharesOfCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690080</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ATNF:WarrantsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-12-01</xbrli:startDate>
        <xbrli:endDate>2021-12-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>SECURITIES AND EXCHANGE
COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>WASHINGTON, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>FORM <span id="xdx_905_edei--DocumentType_c20211201__20211201_zx5WwEBS7kDj"><ix:nonNumeric contextRef="From2021-12-01to2021-12-01" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>PURSUANT TO SECTION
13 OR 15(d) OF THE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>SECURITIES EXCHANGE
ACT OF 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Date of Report (Date of
earliest event reported): <span id="xdx_90C_edei--DocumentPeriodEndDate_c20211201__20211201_zUqzDPAGvfwf"><ix:nonNumeric contextRef="From2021-12-01to2021-12-01" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">December 1, 2021</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b><span style="text-decoration: underline"><span id="xdx_900_edei--EntityRegistrantName_c20211201__20211201_zjm6HPTuwoe2"><ix:nonNumeric contextRef="From2021-12-01to2021-12-01" name="dei:EntityRegistrantName">180 LIFE SCIENCES
CORP.</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">(Exact Name of Registrant
as Specified in Charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; width: 32%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_903_edei--EntityIncorporationStateCountryCode_c20211201__20211201_zPxMRJyAL8s2"><ix:nonNumeric contextRef="From2021-12-01to2021-12-01" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom; width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; width: 32%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_901_edei--EntityFileNumber_c20211201__20211201_zatTWGLXlln1"><ix:nonNumeric contextRef="From2021-12-01to2021-12-01" name="dei:EntityFileNumber">001-38105</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom; width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; width: 32%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_906_edei--EntityTaxIdentificationNumber_c20211201__20211201_zv0gB1HLAwAg"><ix:nonNumeric contextRef="From2021-12-01to2021-12-01" name="dei:EntityTaxIdentificationNumber">90-1890354</ix:nonNumeric></span></b></span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">(State or Other Jurisdiction<br />
of Incorporation)</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">(Commission File Number)</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">(IRS Employer<br />
Identification No.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; width: 49%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_902_edei--EntityAddressAddressLine1_c20211201__20211201_zDKoqBnXmxda"><ix:nonNumeric contextRef="From2021-12-01to2021-12-01" name="dei:EntityAddressAddressLine1">3000 El Camino Real</ix:nonNumeric></span>, <span id="xdx_90A_edei--EntityAddressAddressLine2_c20211201__20211201_zWq9CufiEnkc"><ix:nonNumeric contextRef="From2021-12-01to2021-12-01" name="dei:EntityAddressAddressLine2">Bldg. 4</ix:nonNumeric></span>, <span id="xdx_90A_edei--EntityAddressAddressLine3_c20211201__20211201_zOz1JRlmJuBj"><ix:nonNumeric contextRef="From2021-12-01to2021-12-01" name="dei:EntityAddressAddressLine3">Suite
    200</ix:nonNumeric></span></b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_902_edei--EntityAddressCityOrTown_c20211201__20211201_zjO8oQ86pwlg"><ix:nonNumeric contextRef="From2021-12-01to2021-12-01" name="dei:EntityAddressCityOrTown">Palo Alto</ix:nonNumeric></span>, <span id="xdx_90E_edei--EntityAddressStateOrProvince_c20211201__20211201_z6NbrLTCzZu"><ix:nonNumeric contextRef="From2021-12-01to2021-12-01" name="dei:EntityAddressStateOrProvince">CA</ix:nonNumeric></span></b></p></td>
    <td style="vertical-align: bottom; width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 49%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_903_edei--EntityAddressPostalZipCode_c20211201__20211201_zRTWtd8lH44l"><ix:nonNumeric contextRef="From2021-12-01to2021-12-01" name="dei:EntityAddressPostalZipCode">94306</ix:nonNumeric></span></b></span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">(Address of Principal Executive Offices)</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">(Zip Code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Registrant&#8217;s telephone
number, including area code: <b><span style="text-decoration: underline"><span id="xdx_907_edei--CityAreaCode_c20211201__20211201_zB3eWHlhdfIl"><ix:nonNumeric contextRef="From2021-12-01to2021-12-01" name="dei:CityAreaCode">(650)</ix:nonNumeric></span> <span id="xdx_901_edei--LocalPhoneNumber_c20211201__20211201_zT0az5VNS3rd"><ix:nonNumeric contextRef="From2021-12-01to2021-12-01" name="dei:LocalPhoneNumber">507-0669</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Check the appropriate
box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions (<i>see&#160;</i>General Instruction A.2. below):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15pt; text-align: justify; text-indent: -0.15pt; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_edei--WrittenCommunications_c20211201__20211201_zdluJmVZcjUd"><ix:nonNumeric contextRef="From2021-12-01to2021-12-01" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify">Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_edei--SolicitingMaterial_c20211201__20211201_z0RAm9kzVM97"><ix:nonNumeric contextRef="From2021-12-01to2021-12-01" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify">Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_edei--PreCommencementTenderOffer_c20211201__20211201_zq8rJbheoaA9"><ix:nonNumeric contextRef="From2021-12-01to2021-12-01" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify">Pre-commencement communications pursuant to Rule 14d-2(b)&#160;under
the Exchange Act (17 CFR 240.14d-2(b))</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_edei--PreCommencementIssuerTenderOffer_c20211201__20211201_zgFtahjoPdoc"><ix:nonNumeric contextRef="From2021-12-01to2021-12-01" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify">Pre-commencement communications pursuant to Rule 13e-4(c)&#160;under
the Exchange Act (17 CFR 240.13e 4(c))</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Securities registered
pursuant to Section 12(b)&#160;of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-size: 10pt"><b>Title of each class</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-size: 10pt"><b>Trading Symbol(s)</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-size: 10pt"><b>Name of each exchange on<br />
 which registered</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_909_edei--Security12bTitle_c20211201__20211201__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValue0.0001PerShareMember_z6ngvDGM78Rc"><ix:nonNumeric contextRef="From2021-12-012021-12-01_custom_CommonStockParValue0.0001PerShareMember" name="dei:Security12bTitle">Common Stock, par value $0.0001 per share</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_900_edei--TradingSymbol_c20211201__20211201__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValue0.0001PerShareMember_z76CT4mYpvp3"><ix:nonNumeric contextRef="From2021-12-012021-12-01_custom_CommonStockParValue0.0001PerShareMember" name="dei:TradingSymbol">ATNF</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">The <span id="xdx_903_edei--SecurityExchangeName_c20211201__20211201__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValue0.0001PerShareMember_z9jwiYxjgb2l"><ix:nonNumeric contextRef="From2021-12-012021-12-01_custom_CommonStockParValue0.0001PerShareMember" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric></span> Stock Market LLC</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_90D_edei--Security12bTitle_c20211201__20211201__us-gaap--StatementClassOfStockAxis__custom--WarrantsToPurchaseSharesOfCommonStockMember_zZ80ttsjbhAa"><ix:nonNumeric contextRef="From2021-12-012021-12-01_custom_WarrantsToPurchaseSharesOfCommonStockMember" name="dei:Security12bTitle">Warrants to purchase shares of Common Stock</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_903_edei--TradingSymbol_c20211201__20211201__us-gaap--StatementClassOfStockAxis__custom--WarrantsToPurchaseSharesOfCommonStockMember_zIp55ShAiC9b"><ix:nonNumeric contextRef="From2021-12-012021-12-01_custom_WarrantsToPurchaseSharesOfCommonStockMember" name="dei:TradingSymbol">ATNFW</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">The <span id="xdx_907_edei--SecurityExchangeName_c20211201__20211201__us-gaap--StatementClassOfStockAxis__custom--WarrantsToPurchaseSharesOfCommonStockMember_z0fy86XU2Vsc"><ix:nonNumeric contextRef="From2021-12-012021-12-01_custom_WarrantsToPurchaseSharesOfCommonStockMember" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric></span> Stock Market LLC</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Indicate by check mark
whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter)&#160;or
Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Emerging growth company <span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_edei--EntityEmergingGrowthCompany_c20211201__20211201_zPGFHN4yaGnc"><ix:nonNumeric contextRef="From2021-12-01to2021-12-01" format="ixt:booleantrue" name="dei:EntityEmergingGrowthCompany">&#9746;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with
any new or revised financial accounting standards provided pursuant to Section 13(a)&#160;of the Exchange Act. <span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_edei--EntityExTransitionPeriod_c20211201__20211201_z7OxgxwuOZEc"><ix:nonNumeric contextRef="From2021-12-01to2021-12-01" format="ixt:booleanfalse" name="dei:EntityExTransitionPeriod">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></p>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"><span style="font-size: 10pt"><b>Item
7.01. Regulation FD Disclosure</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">On December
1, 2021, 180 Life Sciences Corp. (the &#8220;<span style="text-decoration: underline">Company</span>&#8221;) issued a press release relating
to a keynote address presented by Prof. Jagdeep Nanchahal (a consultant to the Company and the Chairman of our Clinical Advisory Board),
at the 2021 International Dupuytren Symposium, held on December 1, 2021, including top line data from the Company&#8217;s phase 2b clinical
trial associated with the use of adalimumab as a potential therapeutic target to help treat Dupuytren&#8217;s disease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">A
copy of the press release is furnished hereto as&#160;<span style="text-decoration: underline">Exhibit&#160;99.1</span>.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">A
transcript of Prof. Nanchahal&#8217;s presentation is furnished herewith as <span style="text-decoration: underline">Exhibit 99.2</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
information in&#160;<span style="text-decoration: underline">Item 7.01</span>&#160;of this Form 8-K and&#160;<span style="text-decoration: underline">Exhibits 99.1</span>, and <span style="text-decoration: underline">99.2</span>,&#160;attached hereto, shall
not be deemed &#8220;<span style="text-decoration: underline">filed</span>&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;<span style="text-decoration: underline">Exchange
Act</span>&#8221;) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing
under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
The furnishing of this Report is not intended to constitute a determination by the Company that the information is material or that the
dissemination of the information is required by Regulation FD.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
press release furnished as&#160;<span style="text-decoration: underline">Exhibit 99.1</span>&#160;to this Current Report on Form 8-K and the transcript furnished as <span style="text-decoration: underline">Exhibit
99.2</span>, contain forward-looking statements within the safe harbor provisions under The Private Securities Litigation Reform Act of 1995,
and, as such, may involve known and unknown risks, uncertainties and assumptions. These forward-looking statements relate to the Company&#8217;s
current expectations and are subject to limitations and qualifications set forth in the press release and transcript, and as well as in
the Company&#8217;s other filings with the Securities and Exchange Commission, including, without limitation, that actual events and/or
results may differ materially from those projected in such forward-looking statements. These statements also involve known and unknown
risks, which may cause the results of the Company, its divisions and concepts to be materially different than those expressed or implied
in such statements. Accordingly, readers should not place undue reliance on any forward-looking statements. Forward-looking statements
may include comments as to the Company&#8217;s beliefs and expectations as to future financial performance, events and trends affecting
its business and are necessarily subject to uncertainties, many of which are outside the Company&#8217;s control. More information on
potential factors that could affect the Company&#8217;s financial results is included from time to time in the &#8220;<span style="text-decoration: underline">Forward-Looking
Statements,</span>&#8221; &#8220;<span style="text-decoration: underline">Risk Factors</span>&#8221; and &#8220;<span style="text-decoration: underline">Management&#8217;s Discussion and Analysis of Financial Condition
and Results of Operations</span>&#8221; sections of the Company&#8217;s periodic and current filings with the SEC, including the Form 10-Qs
and Form 10-Ks, filed with the SEC and available at www.sec.gov. Forward-looking statements speak only as of the date they are made. The
Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information,
future events or otherwise that occur after that date, except as otherwise provided by law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>Disclaimer</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The information
contained in the transcript furnished as <span style="text-decoration: underline">Exhibit 99.2</span> is a textual representation of a
video recording of the presentation described above, and while efforts are made to provide an accurate transcription, there may be material
errors, omissions or inaccuracies in the reporting of the substance of the recording. The Company does not assume any responsibility for
any investment or other decisions made based upon the information provided in this transcript. Users are advised to review the video recording
and the Company&#8217;s SEC filings before making any investment or other decisions. An archived recording of the presentation is accessible
through the International Dupuytren website at https://dupuytrensymposium.org/scientific-program.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The link
to the website above is provided for informational purposes only and we make no representations regarding such website, the information
thereon, or any links accessible therefrom, and do not desire to incorporate any of the information on, or accessible through, such website
into this report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"><span style="font-size: 10pt"><b>Item
9.01. Financial Statements and Exhibits</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; background-color: white"><b>(d) Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; width: 9%"><span style="font-size: 10pt"><b>Exhibit No.</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 90%"><span style="font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">99.1*</span></td>
    <td>&#160;</td>
    <td><a href="ea151570ex99-1_180lifesci.htm"><span style="font-size: 10pt">Press Release dated December 1, 2021</span></a></td></tr>
  <tr style="vertical-align: top; background-color: transparent">
    <td><span style="font-size: 10pt">99.2*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="ea151570ex99-2_180lifesci.htm">Transcript of presentation presented by Prof. Jagdeep Nanchahal, at the 2021 International Dupuytren Symposium, held on December 1, 2021</a></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCECFF">
    <td><span style="font-size: 10pt">104</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-size: 10pt">Furnished herewith.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Date: December 1, 2021</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td colspan="2"><span style="font-size: 10pt"><b>180 LIFE SCIENCES CORP.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%">&#160;</td>
    <td style="width: 4%"><span style="font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; width: 36%"><span style="font-size: 10pt"><i>/s/ James N. Woody, M.D., Ph.D.</i></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Name: James N. Woody, M.D., Ph.D.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Title: &#160;Chief Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">2</p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"></p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJx1kUFOwzAQRU/QO4willFrB7ogO4igQqQQtVVh66YTajXxRGOn0CNxSxynFV2AZckazbz//8hRFEczetQ1MrzfL3JYYdPWyiEssEJGU6KfyJ6eU/DvAj+0dayMC+UZzMgz6JnpWIqNb4TRg7a4TUHKybWYJBLEbTq9gWIejfp+RqbSWzROqxqU2ULB1LJGp/g4KKzUFxlqjsFqjWw1GS83FkP7GxIhE3ihg/ok3lvI8ywaxeGMohlT1/Y2nXXUwEONjfeyA/p7Q5QyzKRvivvN7IqKjsudsrjcKUb7Wvn9GjJLR+V+js0G2UNSJN7/7hTmzIIjaE802IADVTAIQFD4w/lCv1C8VnWHYiyEkAVyyPCP66VsDK1iOPQsXA00tP5vQoiz5w9KzJS+ -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea151570ex99-1_180lifesci.htm
<DESCRIPTION>PRESS RELEASE DATED DECEMBER 1, 2021
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>180 Life Sciences Corp. Co-Founder Prof. Jagdeep Nanchahal Presents
Keynote Address at the 2021 International Dupuytren Symposium, including top line data from the phase 2b clinical trial</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&lsquo;Cellular and Molecular Profiling of Dupuytren&rsquo;s Disease:
from the Lab to the Clinic&rsquo; Presented Wednesday, December 1, 2021, at 3pm EST</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">PALO ALTO, Calif., December 1,
2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (&ldquo;180 Life Sciences&rdquo; or the &ldquo;Company&rdquo;), a clinical-stage
biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain,&nbsp;today
announced that </FONT>Professor Jagdeep Nanchahal from the University of Oxford, a co-founder of&nbsp;180 Life Sciences, presented a keynote
address entitled &lsquo;Re-purposing anti-TNF for Dupuytren&rsquo;s Disease&rsquo; at the 2021 International Dupuytren Symposium&nbsp;on
Wednesday, December 1, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As part of the keynote address, Professor Nanchahal described how his
team unraveled the molecular mechanisms underlying the pathogenesis of Dupuytren&rsquo;s disease leading to the identification of Tumor
Necrosis Factor (TNF) as a potential therapeutic target and clinical trials he led to identify the optimal dose and formulation of adalimumab,
an anti-TNF biologic.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At the keynote, he also disclosed the top line data from the phase
2b clinical trial, for patients with early-stage disease, which met the primary end point of nodule hardness and the secondary end point
of nodule size on ultrasound scan with statistically significant differences. There were no related severe adverse events. The full results
have been submitted for publication in a peer-reviewed journal and will be disclosed on publication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Additional information regarding Prof. Nanchahal&rsquo;s address, found
in the Current Report on Form 8-K which 180 Life Sciences filed today with the Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The below is a link to the video presentation of Prof. Nanchahal&rsquo;s
address which will be accessible through the International Dupuytren website (https://dupuytrensymposium.org/scientific-program/).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>About 180 Life Sciences Corp.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">180 Life Sciences Corp. is a clinical-stage
biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by
leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University.
180 Life Sciences is leading the research into solving one of the world&rsquo;s biggest drivers of disease &ndash; inflammation. The Company
is driving groundbreaking studies into clinical programs, which are seeking to develop novel drugs addressing separate areas of inflammation
for which there are no effective therapies. The Company&rsquo;s primary platform is a novel program to treat fibrosis using anti-TNF (tumor
necrosis factor).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B></B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">This press release includes &quot;forward-looking
statements&quot;, including information about management&rsquo;s view of the Company&rsquo;s future expectations, plans and prospects,
within the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 (the &ldquo;Act&rdquo;). Words such as &ldquo;expect,&rdquo;
&ldquo;estimate,&rdquo; &ldquo;project,&rdquo; &ldquo;budget,&rdquo; &ldquo;forecast,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo;
&ldquo;plan,&rdquo; &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;could,&rdquo; &ldquo;should,&rdquo; &ldquo;believes,&rdquo; &ldquo;predicts,&rdquo;
&ldquo;potential,&rdquo; &ldquo;continue&rdquo; and similar expressions are intended to identify such forward-looking statements. These
forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the
expected results and, consequently, you should not rely on these forward-looking statements as predictions of future events. These forward-looking
statements and factors that may cause such differences include, without limitation, statements relating to expectations regarding the
capitalization, resources, and funding of the Company; statements regarding adalimumab&rsquo;s potential as a treatment for Dupuytren&rsquo;s
disease; that the top-line data 180 Life Sciences has reported is based on preliminary analysis of key efficacy and safety data, and such
data may change following a more comprehensive review of the data related to the clinical trial and such top-line data may not accurately
reflect the complete results of the trial expectations with respect to future performance, growth and anticipated acquisitions; the continued
listing of the Company on The NASDAQ Stock Market; expectations regarding the capitalization, resources and ownership structure of the
Company; expectations with respect to future performance, growth and anticipated acquisitions; the ability of the Company to execute its
plans to develop and market new drug products and the timing and costs of these development programs; estimates of the size of the markets
for its potential drug products; potential litigation involving the Company or the validity or enforceability of the intellectual property
of the Company; global economic conditions; geopolitical events and regulatory changes; the expectations, development plans and anticipated
timelines for the Company's drug candidates, pipeline and programs, including collaborations with third parties; access to additional
financing, and the potential lack of such financing; and the Company&rsquo;s ability to raise funding in the future and the terms of such
funding. These risk factors and others are included from time to time in documents the Company files with the Securities and Exchange
Commission, including, but not limited to, its Form 10-Ks, Form 10-Qs and Form 8-Ks. These reports and filings are available at www.sec.gov.
All subsequent written and oral forward-looking statements concerning the Company, the studies described herein or other matters and attributable
to the Company or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers
are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made, including the forward-looking
statements included in this press release, which are made only as of the date hereof. The Company cannot guarantee future results, levels
of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. The Company
does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statement
to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based, except
as otherwise provided by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Investors:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Jason Assad</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Director of IR</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">180 Life Sciences Corp</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">(678) 570-6791</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><U>Jason@180lifesciences.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Media Relations:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Russo Partners</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">David Schull</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><U>David.Schull@russopartnersllc.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">(212) 845-4271&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>ea151570ex99-2_180lifesci.htm
<DESCRIPTION>TRANSCRIPT OF PRESENTATION PRESENTED BY PROF. JAGDEEP NANCHAHAL, AT THE 2021 INTERNATIONAL DUPUYTREN SYMPOSIUM, HELD ON DECEMBER 1, 2021
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Transcript of keynote address presented
by Prof. Jagdeep Nanchahal, at the 2021 International Dupuytren Symposium, held on December 1, 2021</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Speaker: Prof. Jagdeep Nanchahal</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I would like to start by thanking the organizers
for inviting me to present this keynote lecture I&rsquo;ve also taken the liberty of slightly amending the title of my presentation as I would
like to take this opportunity to present my journey of the work that spans a period of over 14 years of how we dissected the cellular
and molecular profile of Dupuytren&rsquo;s disease, identified key signaling mechanisms and how I translated these findings through to Phase
2 clinical trials</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dupuytren&rsquo;s disease is incredibly common and this
is the real issue, that treatment options are currently limited to late stage disease. We&rsquo;ve heard over the last few weeks at this
Symposium we can cut it out or we can disrupt it with needles or collagenase, but this isn&rsquo;t what patients want. They know when
their Dupuytren&rsquo;s disease is at an early stage and currently there&rsquo;s no validated approved treatment. In our review here in 2016 and we
assessed the available literature and found that in fact there are no clinical trials with control groups and blinding of the participants
and the assessors for some of the current treatment options that are used, such as intralesional steroid injection or radiotherapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">What I just described is rather reminiscent of
we used to see patients with rheumatoid arthritis back in the 1990s when I was a surgical trainee. Patients used to present with florid
synovitis, which we as surgeons used to excise and invariably reoccurred, and some clinicians suggested that patient should even be treated
with radiotherapy. It was only when this group back in 1989 defined TNF as a potential therapeutic target that totally changed that landscape
of how these patients were managed. They went on to get the Lasker award and Anti TNF has essentially gone on to become the standard of
care together with a whole host of other monoclonal antibodies such as IL-6R etc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Today I&rsquo;m going to describe how my group is dissected
out the cellular and molecular profile of Dupuytren&rsquo;s disease, the underlying cellular mechanisms. How the various subgroups of cells
maintains the disease ecosystem characterized by chronic low-grade inflammation, how we identified TNF as a potential therapeutic target,
the data from our dose ranging Phase 2A Clinical trial which has been published. I&rsquo;ll also share with you the top line data of the Phase
2B Clinical Trial in patients with early stage Dupuytren&rsquo;s disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The early stage of DD is represented by these
highly cellular nodules. Our single cell RNA sequencing and CyTOF studies show that they comprise a mixed population of fibroblasts, myofibroblasts,
endothelial cells, immune cells and pericytes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Let me take you through these each in turn. First
the fibroblasts. These are not a homogeneous population and there at least four stop sets. I draw your attention in particular to this
ICAM1+ IL6 high which are relatively small population especially enriched within the nodules and they play a key role in attracting the
immune cells to the site of disease. The myofibroblasts are also not homogeneous. They range from this ACTA2 low group, to intermediate
to a CD82 high population, which is highly contractile as shown here in this single cell contractility assay. It is these intermediate
and CD82 high cells that are mainly responsible for matrix production and remodeling. The cycling population don&rsquo;t contribute very much
to matrix production, instead they do exactly what their name suggests, they maintain the pool of myofibroblasts. We also looked at the
different immune cells and as you can see there are several different subsets macrophages, dendritic cells, T cells and not apparent in
this sequencing study, because the numbers are too small, we also see very low numbers for mast cells, which are very important.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">With
freshly disaggregated cells from nodules we see a whole array of cytokines being produced. I don&rsquo;t want to take you through all
of these. However, I&rsquo;d like to draw your attention in particular to TGF</FONT><FONT STYLE="font-family: Symbol">b</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">,
which is the archetype of cytokine associated with fibrosis. you can see about 300pg/ml, relatively large amounts of IL-6, quite small
amounts of TNF, around 50pg/ml and even lower amounts of IL-33. We tested the effects of many of these in functional assays and I will
not take you through all of these, but let&rsquo;s look at a couple of key ones. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">I
will start by defining the effects of TNF in the various cell populations. This was particularly interesting because what we found was
that very low levels, around 100pg/ml with the dose broken down here somewhere between 50 and 100pg/ml, only palmar fibroblasts from Dupuytren&rsquo;s
patients became much more contractile, but at higher doses it is inhibitory and interestingly if you take non-palmar cells from the same
Dupuytren&rsquo;s patients they didn&rsquo;t respond in the same way and neither did palmar cells for normal individuals; in fact they become less
contractile but at much higher concentrations of TNF. If you take myofibroblasts from Dupuytren&rsquo;s patients and expose them to the anti
TNFs, here the data is showing the data for the approved anti TNF agents that are used for other conditions such as rheumatoid arthritis,
you see downregulation contractility which is accompanied by down regulation of </FONT><FONT STYLE="font-family: Symbol">a</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">SMA
protein and COL1messenger RNA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
results of TGF</FONT><FONT STYLE="font-family: Symbol">b</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">are very different.
This cytokine converts all cell types, irrespective of their origin, into much more contractile myofibroblast cells but at much higher
concentrations than we see physiologically. You&rsquo;ll recall those freshly disaggregated cells from the nodules TGF</FONT><FONT STYLE="font-family: Symbol">b</FONT>
<FONT STYLE="font-family: Times New Roman, Times, Serif">levels are around 300pg/ml. We begin to see effects now at about 1,000 and even
10,000pg/ml. It is acting indiscriminately and predictably when you inhibit TGF</FONT><FONT STYLE="font-family: Symbol">b</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">,
you see a downregulation of myofibroblast contractility as well as downregulation of </FONT><FONT STYLE="font-family: Symbol">a</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">SMA
protein and COL1 expression. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">I&rsquo;ve
shown you data that inhibition of either TNF or TGF</FONT><FONT STYLE="font-family: Symbol">b</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">is
effective in down regulating the myofibroblast phenotype. So why select TNF when in freshly dissected nodular cells we see around 50 picograms
per ml of TNF and around 300 picograms per ml of TGF</FONT><FONT STYLE="font-family: Symbol">b</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">in
the supernatant. The cells are often sub-cultured up to passage 5 or 6 and already at passage 2 we see the TNF concentrations falling
off because the immune cells have largely disappeared. Because of autocrine secretion by the stromal cells we now seeing a huge upregulation
of TGF</FONT><FONT STYLE="font-family: Symbol">b</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">production. So this suggests
that TGF levels seen here later passaged cells is a culture artifact and this goes some way to explaining the failure of targeting TGF
in multiple late Phase clinical trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">My
colleague, Dominic Furniss in Oxford and Paul Werker from Groningen have shown the key role of Wnt signaling pathways in Dupuytren's disease
through their genome wide association studies. We went on the show that TNF only in palmar fibroblast from Dupuytren's patients acts via
the Wnt signaling pathway to upregulate genes such COL1 and </FONT><FONT STYLE="font-family: Symbol">a</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">SMA
typically associated with fibrosis. And now we have both molecular and genetic data supporting TNF as a potential therapeutic target.
We know that the genetics of Dupuytren's disease is incredibly important as a hereditability about 80% but Dupuytren's disease is restricted
to the palm of genetically susceptible individuals so this suggests that epigenetic regulation must play a key role and indeed it does.
Histone acetylation is associated with increased gene expression and what we have shown is that histone acetylation in myofibroblasts
is crucial in maintaining their phenotype. Conversely methylation suppresses gene expression and our most recent data show that this mechanism
is important in regulating cytokine expression by those immune regulatory fibroblasts through an intermediatory molecule called PLAG2G2A.
So suppression of these genes leads to increased expression CCL2 &amp; CCL7, which in turn recruit the immune cells and these produced
the TNF that drives the myofibroblast phenotype. </FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dupuytren&rsquo;s disease persists and develops
over a period of many decades. Typically inflammation in humans occurs and then resolves over a period of weeks and months. What we see
here in Dupuytren&rsquo;s disease is the inflammation persisting over very long period. What we found is that those immune cells produce
TNF which drives the development of myofibroblasts and these in turn produce low levels of cytokine called IL-33, which in turn acts on
the immune cells and hence we get this vicious cycle whereby the information persists over very long period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our most recent data has showed that that the
various cell types that I&rsquo;ve described are not randomly distributed through the nodule but in fact compartmentalized so you have
these immune regulatory fibroblasts which attract the immune cells which in turn produce TNF which drives the myofibroblasts phenotype,
but these immune regulatory fibroblasts are maintained by platelet derived growth factor produced by the fibrotic endothelium and there
is this relative segregation of the myofibroblast compartment from the remainder. We see a very similar pattern here in lung fibrosis
in patients with a idiopathic pulmonic fibrosis. So segregated myofibroblasts and then these immune regulatory fibroblasts and blood vessels
around the myofibroblast foci.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Having identified TNF as a potential therapeutic target
I applied to the Wellcome Trust and Department of Health for funding to undertake a Phase 2A followed by a Phase 2B randomized clinical
trial. For Phase 2A if we were to use clinical outcome measures, we&rsquo;d need relatively large number of patients in each group. So
instead I chose an experimental medicine design including patients were already scheduled for surgery but who had large prominent nodules
in the palm of their hand that were to have been excised at the time of surgery. We injected those nodules with different doses of anti-TNF
or an equivalent volume of placebo in a blinded manner collected the tissue after surgery and then analyzed it in the lab for various
markers which I will show you in moment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Having identified the optimal dose of the anti-TNF
we then preceded to a Phase 2B clinical trial where we were treated patients with early stage disease and prominent nodule with a clear
history of activity within that nodule and patients were randomized to receive either that optimal dose of anti-TNF or an equivalent volume
of saline. Now adalimumab as you know in patients with rheumatoid arthritis is administered every two weeks. However our patients would
not tolerate 2 injections every two weeks so we did end user survey. We asked patients with both early and late stage disease how many
injections a year would they accept to control their Dupuytren&rsquo;s disease. Almost all said one injection a year the majority said
two and three and once we get to about four the positive responses were beginning to fall off. On that basis we designed the trial such
that patients would receive 4 injections of the TNF and an equivalent volume of placebo every three months for a year and then we followed
them for a total of 18 months. Dupuytren&rsquo;s diseases is a localized low grade inflammatory disease I hypothesized that if the anti-TNF
is going to be effective it has to be delivered locally into the nodule at high concentrations. The nodules can be identified clinically
and here you can see them with ultrasound scan. What we found with our ex vivo studies that around 0.3 to 0.5 ml remains constrained within
the nodule, and after that it just begins to spill out.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">So this is the design of the first Phase 2A Clinical
Trial. These are patients with nodules that are going to be excised and two weeks before their surgery we injected them with different
doses of adalimumab so we first injected them with 15mg in 0.3 ml or an equivalent volume of saline, next 35mg in 0.7 ml or equivalent
volume of saline and it was at this stage that I notice that the 0.7 ml is not remaining constrained within the nodule as we&rsquo;ve seen in
the ex vivo studies but in fact was spilling out into the subcutaneous space.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Now
I had hypnotized that we would need high local concentrations of anti-TNF if it were to be effective because this is a localized fibrotic
disease and by coincidence the manufacturer that point brought in a new formulation much more concentrated at 40mg in 0.4 ml. The great
thing about this formulation is that is was free of excipients such as citrate which it should be associated with lower pain on injection.
So we submitted a major protocol amendment incorporating additional dose forward before we had analyzed and unblinded data so we now had
three different doses 15, 35 and 40mg in different volumes. Having collected the tissue we then analyzed it in a blinded manner 2 weeks
following the injection of the anti-TNF or equivalent volume of placebo. We found was that only the 40mg in 0.4 ml led to a downregulation
in </FONT><FONT STYLE="font-family: Symbol">a</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">SMA protein concentration
as well as collagen I protein concentration. Contrast that with the 35 milligrams - for very similar amounts of adalimumab and half the
concentration in this had no effect on either </FONT><FONT STYLE="font-family: Symbol">a</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">SMA
or collagen I. so this study allowed us to identify the optimal dose and formulation and we can then take forward to the next stage of
our study.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We published the results of our Phase 2A Clinical
Trial in EBiomedicine in 2018. Having identified the optimal dose and formulation about adalimumab to use for local administration in
patients with Dupuytren&rsquo;s disease, we preceded to a randomized double blind placebo controlled trial. We recruited patients with
early stage Dupuytren&rsquo;s disease who did not have established flexion deformities that would be treated surgically but did have a
prominent nodule with a clear recent history of progression. The first question we asked was how often to inject the nodule. Adalimumab
is administered every two weeks for patients with inflammatory arthritis we did not think that two weekly injections which can be painful
will be tolerated therefore we conducted an end user survey we asked patients with early and patients with late stage disease how many
injections will be acceptable every year to control the progression of Dupuytren&rsquo;s disease. All agreed one, most said 2 or 3 but
after four the acceptability started to fall off. Therefore, we selected 4 injections at three monthly intervals. The next question was
which outcome measure to use. Correction of established flection deformities has been used in studies for patients with late-stage disease
for example following treatment with collagenase. However using the converse, prevention of flexion deformity poses difficulties. The
available data suggests that without treatment 20% of patients with early-stage disease progressed to develop flection deformities over
seven years and about 35% by 18 years. These long timescales would mean that we would have to follow patients for ten years or more, which
is not feasible in the context of a clinical trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Nodule hardness has been uses to access efficacy
for example in patients receiving intralesional corticosteroid injections. However in these studies unblinded clinicians assessed clinically
whether the is the nodule softer. We wanted to quantitatively measure module hardness. Our literature search revealed that a durometer
has been found to be reliable and sensitive for assessing skin hardness in patients with scleroderma, lipodermatosclerosis and scars.
Therefore, we use the same durometer. The next challenge we faced was how to calculate sample size. In a pilot study independent we assessed
the hardness of nodules in 25 patients in early-stage disease and the corresponding area in the palm of age, sex matched controls. This
gave us the difference and standard deviation to calculate sample size. Our pilot data also showed that we could reliably image the nodule
using ultrasound skin. Therefore, we measured nodule size using ultrasound scan as a secondary outcome measures as well as various clinical
outcomes including patient reported measures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At this stage I can share with you the top line
data of this phase 2B clinical trial. We met the primary endpoint of nodule hardness and the secondary endpoint of nodule size using ultrasound
scan, with statistically significant differences. The full results have been submitted for publication in a peer reviewed journal and
will be disclosed on publication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In summary, I have shown you our data that the
nodules of early stage Dupuytren&rsquo;s disease comprise a complex ecosystem of vascular and immune cells, fibroblasts and myofibroblasts.
There&rsquo;s also clear division of Labor between each of the cell types. The individual cells secrete growth factors to sustain the immune
regulatory fibroblasts. These fibroblasts in turn recruit the immune cells. The immune cells secrete cytokines that promotes myofibroblast
development and there are distinct populations of myofibroblasts, a small cycling pool and others that are mainly responsible for matrix
production and contractility.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A complex cross talk between the stromal and immune
cells maintains the chronic low grade localized inflammation characteristic of early stage Dupuytren&rsquo;s disease. Epigenetic regulation
is also very important in the modulation of activities of the immune regulatory fibroblasts and myofibroblasts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A detailed understanding of the mechanisms underlying
Dupuytren&rsquo;s disease has allowed us to identify TNF as a potential therapeutic target. We identified the optimal dose and formulation
about adalimumab in our Phase 2A clinical trial and I described the top line data of our Phase 2B clinical trial, where we met the primary
endpoint of nodule hardness and the secondary endpoint of nodular size on ultrasound scans, both with statistically significant differences.
There were no related serious adverse events in the Phase 2B trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I would like to finish by acknowledging my laboratory
team as well others not shown here. The Clinical Trials team, my colleagues in the Oxford Clinical Trials Research Unit and many collaborators,
Dominic Davidson and Paul Werker, in particularly who recruited patients to the RIDD trial as well as surgical colleagues around the country
who sent us patient samples, the patients who donated tissue and I am particularly indebted to the RIDD trial participants who continued
with all of their follow-ups, including between the various lockdowns in 2020. None of this work would be possible without the generous
supporters of various Funding Agencies shown here, the Department of Health and in particular The Wellcome Trust for supporting the RIDD
trial. I&rsquo;ve received industry support for the laboratory studies and also for purchase of the drug for the RIDD trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Please note: 180 Life Sciences Corp. used its best
efforts to provide the foregoing transcript based on the video and audio associated with the presentation, but there cannot be assurance
there are no errors, omissions, or inaccuracies.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">5</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>atnf-20211201.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.10b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: /qpZs7xRiXgen8uBYXYsWaGOOaPtyJ1xqYkxuG9xfQlKHycoXqUdzCWz8jcG4dgH -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:ATNF="http://180lifesciences.com/20211201" elementFormDefault="qualified" targetNamespace="http://180lifesciences.com/20211201">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://180lifesciences.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="atnf-20211201_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="atnf-20211201_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="atnf-20211201_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd" />
    <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
    <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
    <element id="ATNF_CommonStockParValue0.0001PerShareMember" name="CommonStockParValue0.0001PerShareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ATNF_WarrantsToPurchaseSharesOfCommonStockMember" name="WarrantsToPurchaseSharesOfCommonStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>atnf-20211201_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.10b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://180lifesciences.com/role/Cover" xlink:href="atnf-20211201.xsd#Cover" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://180lifesciences.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="atnf-20211201.xsd#ATNF_CommonStockParValue0.0001PerShareMember" xlink:label="loc_ATNFCommonStockParValue0.0001PerShareMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ATNFCommonStockParValue0.0001PerShareMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="atnf-20211201.xsd#ATNF_WarrantsToPurchaseSharesOfCommonStockMember" xlink:label="loc_ATNFWarrantsToPurchaseSharesOfCommonStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ATNFWarrantsToPurchaseSharesOfCommonStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate_40" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate_40" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus_40" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus_40" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate_40" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber_40" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName_40" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey_40" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber_40" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber_40" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode_40" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1_40" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2_40" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3_40" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown_40" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince_40" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry_40" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode_40" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion_40" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode_40" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber_40" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Extension" xlink:label="loc_deiExtension_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension_40" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications_40" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial_40" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer_40" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer_40" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle_40" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag_40" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol_40" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName_40" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle_40" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation_40" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers_40" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus_40" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent_40" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory_40" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness_40" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany_40" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod_40" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard_40" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber_40" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany_40" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat_40" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent_40" xlink:type="arc" order="55" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding_40" xlink:type="arc" order="56" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock_40" xlink:type="arc" order="57" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>atnf-20211201_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.10b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="atnf-20211201.xsd#ATNF_CommonStockParValue0.0001PerShareMember" xlink:label="ATNF_CommonStockParValue0.0001PerShareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ATNF_CommonStockParValue0.0001PerShareMember" xlink:to="ATNF_CommonStockParValue0.0001PerShareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ATNF_CommonStockParValue0.0001PerShareMember_lbl" xml:lang="en-US">Common Stock, par value $0.0001 per share</link:label>
      <link:loc xlink:type="locator" xlink:href="atnf-20211201.xsd#ATNF_WarrantsToPurchaseSharesOfCommonStockMember" xlink:label="ATNF_WarrantsToPurchaseSharesOfCommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ATNF_WarrantsToPurchaseSharesOfCommonStockMember" xlink:to="ATNF_WarrantsToPurchaseSharesOfCommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ATNF_WarrantsToPurchaseSharesOfCommonStockMember_lbl" xml:lang="en-US">Warrants to purchase shares of Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>atnf-20211201_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.10b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://180lifesciences.com/role/Cover" xlink:href="atnf-20211201.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://180lifesciences.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="atnf-20211201.xsd#ATNF_CommonStockParValue0.0001PerShareMember" xlink:label="loc_ATNFCommonStockParValue0.0001PerShareMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ATNFCommonStockParValue0.0001PerShareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="atnf-20211201.xsd#ATNF_WarrantsToPurchaseSharesOfCommonStockMember" xlink:label="loc_ATNFWarrantsToPurchaseSharesOfCommonStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ATNFWarrantsToPurchaseSharesOfCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>ea151570-8k_180lifesci_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:ATNF="http://180lifesciences.com/20211201"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="atnf-20211201.xsd" xlink:type="simple"/>
    <context id="From2021-12-01to2021-12-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-01</endDate>
        </period>
    </context>
    <context id="From2021-12-012021-12-01_custom_CommonStockParValue0.0001PerShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ATNF:CommonStockParValue0.0001PerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-01</endDate>
        </period>
    </context>
    <context id="From2021-12-012021-12-01_custom_WarrantsToPurchaseSharesOfCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690080</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ATNF:WarrantsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-01</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2021-12-01to2021-12-01">0001690080</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2021-12-01to2021-12-01">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2021-12-01to2021-12-01">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2021-12-01to2021-12-01">2021-12-01</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2021-12-01to2021-12-01">180 LIFE SCIENCES CORP.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2021-12-01to2021-12-01">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2021-12-01to2021-12-01">001-38105</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2021-12-01to2021-12-01">90-1890354</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2021-12-01to2021-12-01">3000 El Camino Real</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2021-12-01to2021-12-01">Bldg. 4</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3 contextRef="From2021-12-01to2021-12-01">Suite     200</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown contextRef="From2021-12-01to2021-12-01">Palo Alto</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2021-12-01to2021-12-01">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2021-12-01to2021-12-01">94306</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2021-12-01to2021-12-01">(650)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2021-12-01to2021-12-01">507-0669</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2021-12-01to2021-12-01">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2021-12-01to2021-12-01">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2021-12-01to2021-12-01">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2021-12-01to2021-12-01">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2021-12-012021-12-01_custom_CommonStockParValue0.0001PerShareMember">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2021-12-012021-12-01_custom_CommonStockParValue0.0001PerShareMember">ATNF</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2021-12-012021-12-01_custom_CommonStockParValue0.0001PerShareMember">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="From2021-12-012021-12-01_custom_WarrantsToPurchaseSharesOfCommonStockMember">Warrants to purchase shares of Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2021-12-012021-12-01_custom_WarrantsToPurchaseSharesOfCommonStockMember">ATNFW</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2021-12-012021-12-01_custom_WarrantsToPurchaseSharesOfCommonStockMember">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2021-12-01to2021-12-01">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="From2021-12-01to2021-12-01">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139630637198872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Dec. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec.  01,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">180 LIFE SCIENCES
CORP.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001690080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">90-1890354<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3000 El Camino Real<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Bldg. 4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">Suite
    200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Palo Alto<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94306<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(650)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">507-0669<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ATNF_CommonStockParValue0.0001PerShareMember', window );">Common Stock, par value $0.0001 per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ATNF<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ATNF_WarrantsToPurchaseSharesOfCommonStockMember', window );">Warrants to purchase shares of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Warrants to purchase shares of Common Stock<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ATNFW<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 3 such as an Office Park</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ATNF_CommonStockParValue0.0001PerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ATNF_CommonStockParValue0.0001PerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ATNF_WarrantsToPurchaseSharesOfCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ATNF_WarrantsToPurchaseSharesOfCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MCKT SJ^E-&\[=OVJ6'X<_@U02P,$%     @ MG6!4^#T.HFJ @  , P   T
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M 0  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSM9$]#H,P#(6O$N4
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M4')O<',O87!P+GAM;%!+ 0(4 Q0    ( +9U@5-))/F:[@   "L"   1
M          "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( +9U
M@5.97)PC$ 8  )PG   3              "  <P!  !X;"]T:&5M92]T:&5M
M93$N>&UL4$L! A0#%     @ MG6!4Y.ZN2?0!   BA0  !@
M ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( +9U
M@5/@]#J)J@(  # ,   -              "  1,-  !X;"]S='EL97,N>&UL
M4$L! A0#%     @ MG6!4Y>*NQS     $P(   L              ( !Z \
M %]R96QS+RYR96QS4$L! A0#%     @ MG6!4ZK$(A8S 0  (@(   \
M         ( !T1   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( +9U@5,D
M'INBK0   /@!   :              "  3$2  !X;"]?<F5L<R]W;W)K8F]O
M:RYX;6PN<F5L<U!+ 0(4 Q0    ( +9U@5-ED'F2&0$  ,\#   3
M      "  183  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(
' & 4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>2</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="ea151570-8k_180lifesci.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://180lifesciences.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="ea151570-8k_180lifesci.htm">ea151570-8k_180lifesci.htm</File>
    <File>atnf-20211201.xsd</File>
    <File>atnf-20211201_def.xml</File>
    <File>atnf-20211201_lab.xml</File>
    <File>atnf-20211201_pre.xml</File>
    <File>ea151570ex99-1_180lifesci.htm</File>
    <File>ea151570ex99-2_180lifesci.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ea151570-8k_180lifesci.htm": {
   "axisCustom": 0,
   "axisStandard": 1,
   "contextCount": 3,
   "dts": {
    "definitionLink": {
     "local": [
      "atnf-20211201_def.xml"
     ]
    },
    "inline": {
     "local": [
      "ea151570-8k_180lifesci.htm"
     ]
    },
    "labelLink": {
     "local": [
      "atnf-20211201_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "atnf-20211201_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "atnf-20211201.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 65,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 2,
   "memberStandard": 0,
   "nsprefix": "ATNF",
   "nsuri": "http://180lifesciences.com/20211201",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "ea151570-8k_180lifesci.htm",
      "contextRef": "From2021-12-01to2021-12-01",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://180lifesciences.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "ea151570-8k_180lifesci.htm",
      "contextRef": "From2021-12-01to2021-12-01",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 2,
   "tag": {
    "ATNF_CommonStockParValue0.0001PerShareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, par value $0.0001 per share"
       }
      }
     },
     "localname": "CommonStockParValue0.0001PerShareMember",
     "nsuri": "http://180lifesciences.com/20211201",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "ATNF_WarrantsToPurchaseSharesOfCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants to purchase shares of Common Stock"
       }
      }
     },
     "localname": "WarrantsToPurchaseSharesOfCommonStockMember",
     "nsuri": "http://180lifesciences.com/20211201",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r9",
      "r11",
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [],
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://180lifesciences.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r10": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r11": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r12": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r13": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r14": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r15": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r16": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "Section",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001213900-21-062812-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-21-062812-xbrl.zip
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M>&ULU5U=<]NV$GWOS/T/K/HLZ\-UV[AQ.XIB=31-8M=RDWOOBP<B(0EC"-
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MU,+IXNF4*2R0K\@#_H@42O"6:6'W:($6)<!!+9QN/(YNU+&.9\G+]P[D#%O
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M$*"N_EY_EUPW/\R?C=%7_@%02P,$%     @ MG6!4P2WN7OT"P  )I   !4
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M(4B58GM_>773M?@D-A>;Q%]SG!*QY?]02P,$%     @ MG6!4T=>,?M,"
M1V,  !4   !A=&YF+3(P,C$Q,C Q7W!R92YX;6S5G=]WVC84Q]]WSOX'CSX3
M(-FO9LUV4AIZ.&N;++!VVTN/L 7H1$@<24[@OY]D; K8DB_MRO7ZD!)S)=WO
MY\JRKBTY+WY;+7CT2)5F4ERU>F?=5D1%+!,F9E>M/T?MZU%_.&Q%VA"1$"X%
MO6H)V?KMUV^_B>R_%]^UV]& 49Y<1J]DW!Z*J?PE>D<6]#)Z3055Q$CU2_2>
M\-0=D0/&J8KZ<K'DU%#[Q:;AR^B'LUYW$K7;@'K?4Y%(]>?]<%OOW)BEONQT
MGIZ>SH1\)$]2/>BS6"Y@%8X,,:G>UM9==?-_F^(O.!,/E^['A&@:65Y"7ZXT
MNVJY=O-FGR[.I)IUSKO=7N>OMV]&\9PN2)L)QRVFK:*4JZ6J7._Y\^>=[-O"
MM&2YFBA>M''1*=S9UFR_90'['4\TN]29>V]D3$P6]MIF(J^%^ZU=F+7=H7;O
MO'W1.UOII%7 SP@JR>D]G4;N?QN];:N]G[N<3:F.F>UX-(M;Q]ET^M+V2^MP
M5GJNZ/2J18R8VD;.>[WS;M;$LSTCLU[:_JF9ZUZMJ+/7_%)1387)%+^Q!_:*
MT)6QO8HF146N_2,=-,RX,GG7Z45MU\_2A6W2?MQ8YOX4'G$9[SG!73SD@>*B
M;V?4-8W/9O*QDU#6<13<APQ'AL+^\C%KZ'JBC2*Q*6KB9$)Y5O]':W-@TOEB
MKZ9$3[(.D>KVC)#EQC7*C2Z.9#ZVN[V\7SS+#W]T9QYUB,9DXB)6<C<W/+0[
M]'DWMM=JWW^BXJ)B^W$OL.7>G%MTED39^MKQG/%MGY@JN?!!S!N40:^E2JBR
M8VRWVQ#J]C2@0_M1 \COV"+3]] -AV#'_3P,YXT)0Y\3K6^G(R/CA^L5@T2C
M7.3_&)2RBNTI@AN:7<=>R05APA^3*MN&!</7P0[B4J4D#\CGQJ-\O;X>OQO8
MJ]1B(476T!U1V;RK>^:NFG=4C>96VUNZF'RZM.Y =\7!I>O"L!T)OE( _-VH
M('^4G%*O^2]#\H$H18318WF7JGAN)W-9V];]'?^"83FJ!F!H+G!#\QE0OC0\
M1\[WBCGFV-98/=W;MP!R_UK8_5./ GO)8Q2LU[;]Q/DPX&16S?7 ! BVATJV
M4A86VE<VHU)LZ0#5$-ZSQ![4CP-=(1)IA+BG,^;2%>?*5D-XR/ 4P1Z[CQI$
M@K*10G$M1$KX/5U*51.!?4L@^.\; ;Y*)!+O/U*B#%5\#4%>,@92_Z$1U#U2
ML68E=O:DF0,%(5^V!J+_L1'H?6*1V(_FE'-WIYT(4+^OL@?R_ZD1_/V"&Q"!
MFT<W&;!JX$'8*0*,P\^-BT-)-E(H;"K-9&)E*$ 02L9 _,\;@=\C%17\C4B@
MV+>FX(2J0=0/="(Q'S =$[[Q:&"/5=U0WG&]PAS*'C>;K=6+RO]O2A28_HXQ
ME#UN@ENC]<3D^ZE2>\X$!QR_-90];FI;I_;$\&^$86;M5G:\2SVWAZU9V0H*
M&S>=]:E#@5S<S!#&K5P)@3ZTA,+&S6)#*E& ]ZW#BO"A2.CJ=[H.$2^90I'C
M9J]!G2C,[Q1;$+4>L;A^/"G;0JGCYJQAI2C8QV0U3*S;;,HVR\+JZ7N+0(.
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M+VU##^&I%* X-%#->"<4F$=%O%YT2@)MDP_VV_P;]\/]U0-[Y%]02P,$%
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M90@%[.DC>Q9/!!". TUUW^S6G4!$$Q?]#-<)+"$N=0M5'%B%O--2#)7"'2,
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M4S68)?#V1&T F0G/1&SK,?!MNEZYBE>,X[5 Q>MBID&,1UVG;UB@H=5_V7E
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M.NTT=H:?#?ZP,RJ</IRT_I&D^7]02P,$%     @ MG6!4T2[R5)C#0  2C
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MBLWO Y/\_C2:J PF&@Y<9Z.PH#]@[5-HR4P#NB%^:'D'<M17I%*P"8#3UK?
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MI/*+I/CATO\'4$L! A0#%     @ MG6!4\MVHQ/9 P  [0X  !$
M     ( !     &%T;F8M,C R,3$R,#$N>'-D4$L! A0#%     @ MG6!4W&+
M5KX%"0  LV@  !4              ( !" 0  &%T;F8M,C R,3$R,#%?9&5F
M+GAM;%!+ 0(4 Q0    ( +9U@5,$M[E[] L  ":0   5              "
M 4 -  !A=&YF+3(P,C$Q,C Q7VQA8BYX;6Q02P$"% ,4    " "V=8%31UXQ
M^TP(  !'8P  %0              @ %G&0  871N9BTR,#(Q,3(P,5]P<F4N
M>&UL4$L! A0#%     @ MG6!4^AS@+S(&@  0Y4  !H              ( !
MYB$  &5A,34Q-3<P+3AK7S$X,&QI9F5S8VDN:'1M4$L! A0#%     @ MG6!
M4T2[R5)C#0  2C   !T              ( !YCP  &5A,34Q-3<P97@Y.2TQ
M7S$X,&QI9F5S8VDN:'1M4$L! A0#%     @ MG6!4XU^<@1V'P  OW0  !T
M             ( !A$H  &5A,34Q-3<P97@Y.2TR7S$X,&QI9F5S8VDN:'1M
64$L%!@     '  < Y@$  #5J      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
